

To,

Date: 14.02.2023

BSE Limited,

Phiroz Jeejeebhoy Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of the Board meeting held on 14.02.2023

Unit: Decipher Labs Limited (Scrip: 524752)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Decipher Labs Limited held on Tuesday, 14th February, 2023 at 4.30 p.m. at its registered office at 4th Floor, Plot No. 94, Sagar Society, Banjara Hills, Road No. 2, Hyderabad – 500034 the following were considered and approved/ noted:

1. Un-audited Financial Results (both standalone and consolidated) for the quarter ended 31.12.2022. **(Enclosed)**
2. Limited Review Report (both standalone and consolidated) for the quarter ended 31.12.2022. **(Enclosed).**
3. Appointment of Mr. Mary Vara Prasad Mutluri (DIN: 01726581) and Mrs. Lakshmi Vijaya Nimmala (DIN: 09788849) as Independent Directors on the Board of the Company for a term of 3 consecutive years w.e.f. 14.02.2023 subject to the approval of members in the ensuing general meeting. (Brief profile is annexed as Annexure – I).
4. Appointment of Mr. Janaki Ram Ajarapu (DIN: 02155939) as a Non-executive Director of the Company w.e.f. 14.02.2023 subject to the approval of members in the ensuing general meeting. (Brief profile is annexed as Annexure – I).



The meeting concluded at 9:30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,

For Decipher Labs Limited

Megha Agarwal

Company Secretary and Compliance Officer

Encl: as above

Annexure - I

The details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

S. No	Particulars	Mr. Mary Vara Prasad Mutluri	Mrs. Lakshmi Vijaya Nimmala	Mr. Janaki Ram Ajjarapu
1.	Reason for change viz. Appointment, Resignation	Appointment	Appointment	Appointment
2.	Date of appointment/cessation	14.02.2023	14.02.2023	14.02.2023
3.	Term of Appointment	Appointed w.e.f. 14.02.2023 up to the ensuing General Meeting or 3 months from the date of appointment whichever is earlier.	Appointed w.e.f. 14.02.2023 up to the ensuing General Meeting or 3 months from the date of appointment whichever is earlier.	Appointed w.e.f. 14.02.2023 up to the ensuing General Meeting or 3 months from the date of appointment whichever is earlier.
4.	Brief Profile (in case of appointment)	Mr. M V Prasad is a highly experienced professional in IT Global Infra & App Service Delivery, Outsourcing & Managed Services, Business Development & Technology Solutions, Advisory Services covering North America, Middle East & India Geographies. He is well versed with the technical as well as financial structures of India and the US. He specializes in Technology Services Solutions, Global Service Delivery and Account Management, Strategizing, building, operating and establishing offshore delivery centers and New Region development for services and product offerings and Scaling up of Operations by Planning &	Mrs. Lakshmi Vijaya Nimmala is a Masters of Business Administration with specialization in Finance and has also worked in the Human Resources department. Her knowledge and experience in Finance and HR solutions adds value to the company.	Mr. Janakiram Ajjarapu is the Promoter of the company. He is a Person of Indian Origin and an NRI. He holds a Master's degree in Business Administration from the University of South Florida with a major in Finance. He has an experience of about 25 years in the fields of Finance, Sales, Marketing, Administration, Information Technology and

		establishing revenue streams in related offerings.		Mergers & Acquisitions.
5.	Relationship with other directors (in case of appointment)	NA	NA	NA
6.	Shareholding if any in the Company	Nil	Nil	16,59,075 Equity Shares
7.	Information as required pursuant to BSE circular with Ref. No. LIST/COMP/14/2018-19	Mr. Mary Vara Prasad Mutluri is not debarred from holding the office of director by virtue of any SEBI Order or any other such authority.	Mrs. Lakshmi Vijaya Nimmala is not debarred from holding the office of director by virtue of any SEBI Order or any other such authority.	Mr. Janaki Ram Ajarapu is not debarred from holding the office of director by virtue of any SEBI Order or any other such authority.

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar Society Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Statement of Standalone Financial Results For the Quarter and Nine months Ended 31st December, 2022

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	2.93	12.23	37.45	68.06	74.38	98.84
II. Other income	0.60	1.26	0.46	2.44	1.37	4.59
III. Total Income (I + II)	3.53	53.49	37.91	70.50	75.75	103.43
IV. Expenses						
Purchase of Stock in trade	2.25	3.15	15.53	36.90	15.53	15.53
Employee benefits expense	4.36	4.24	5.09	12.65	18.85	23.32
Finance Costs	-	-	-	-	-	-
Depreciation expense	1.46	1.45	1.25	4.38	3.60	5.01
Other expenses	4.07	6.32	5.20	22.40	14.93	23.78
Total expenses	12.14	15.17	27.07	76.33	52.90	67.64
V. Profit before Exceptional items (III - IV)	(8.62)	(1.67)	10.84	(5.84)	22.85	35.79
VI. Exceptional items	224.15			224.15		
VII. Profit after Exceptional items (V - VII)	(232.77)			(229.99)		
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.03)	0.38	0.02	0.48	0.12	(0.25)
IX. Profit/(Loss) for the period (VII-VIII)	(232.79)	(2.05)	10.82	(230.47)	22.73	36.04
X. Other comprehensive income						
XI. Total comprehensive income for the year	(232.79)	(2.05)	10.82	(230.47)	22.73	36.04
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share						
(1) Basic	(2.30)	0.02	0.11	(2.28)	0.23	0.36
(2) Diluted	(2.30)	0.02	0.11	(2.28)	0.23	0.36

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Nine Months Ended		Year Ended
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	2.92	4.10	30.02	52.02	30.02	68.82
b) Consultancy Services	(0.00)	8.14	7.43	16.04	44.36	30.02
Total Sales	2.92	12.23	37.45	68.06	74.38	98.84
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	2.92	12.23	37.45	68.06	74.38	98.84
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(8.62)	(0.56)	6.65	(4.46)	6.65	24.92
b) Consultancy Services	0.00	(1.11)	4.19	(1.38)	16.20	10.87
Total	(8.62)	(1.67)	10.84	(5.84)	22.85	35.79
Less: Interest	-	-	-	-	-	-
Total Profit before tax	(8.62)	(1.67)	10.84	(5.84)	22.85	35.79
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	919.19	1,149.84	279.54	919.19	279.54	1,146.31
b) Consultancy Services	12.83	20.82	877.90	12.83	877.90	14.04
Total Assets	932.02	1,170.66	1,157.44	932.02	1,157.44	1,160.35
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	8.97	15.28	17.20	8.97	17.20	8.04
b) Consultancy Services	-	-	1.40	-	1.40	-
c) Unallocated liabilities	0.37	0.94	-	0.37	-	-
Total Liabilities	9.35	16.22	18.60	9.35	18.60	8.04

2. The Exceptional items represents security written off, which are not recoverable.

3. The above results for the quarter ended 31st December 2022 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.02.2023.

4. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

5. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 14.02.2023

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Unaudited Financial Results For the Quarter and Nine months ended 31 December 2022

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine Months Ended		Year Ended
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	1,105.60	1,212.24	1,371.24	3,579.76	4,203.47	6,532.24
II. Other income	(230.78)	266.03	730.37	721.60	751.13	767.40
III. Total revenue (I + II)	874.82	1,478.27	2,101.61	4,301.36	4,954.60	7,299.64
IV. Expenses						
Purchase of Stock-in-Trade	2.25	3.15	15.53	36.90	15.53	15.53
Project Management Cost	-	-	-	-	-	719.17
Employee benefits expense	1,193.75	1,178.20	1,241.97	3,435.13	3,577.74	4,748.68
Finance costs	12.76	11.58	13.59	35.70	33.76	47.66
Depreciation and amortisation expense	10.52	10.48	22.35	30.76	66.82	86.66
Other expenses	206.12	117.65	55.06	565.25	270.28	446.34
Total expenses	1,425.42	1,321.05	1,348.50	4,103.76	3,964.13	6,064.04
V. Profit/(Loss) before Exceptional item (III - IV)	(550.59)	157.22	753.11	197.60	990.47	1,235.60
VI. Exceptional items	224.15	-	-	224.15	-	-
VII. Profit/(Loss) after Exceptional item (III - IV)	(774.74)	157.22	753.11	(26.55)	990.47	1,235.60
VIII. Tax expense:						
(1) Current tax	0.59	37.52	67.55	38.11	119.95	170.44
(2) Deferred tax	(0.03)	0.38	(42.33)	0.48	(73.73)	(73.97)
(3) Tax of earlier years	-	-	-	-	0.76	0.75
IX. Profit/(Loss) for the period (V-VI)	(775.31)	119.32	727.89	(65.15)	943.49	1,138.38
X. Other comprehensive income						
Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	29.39	101.24	4.77	188.59	20.35	56.09
XI. Total comprehensive income for the year	(745.92)	220.56	732.66	123.44	963.84	1,194.47
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share						
(1) Basic	(7.68)	1.18	7.21	(0.65)	9.34	11.27
(2) Diluted	(7.68)	1.18	7.21	(0.65)	9.34	11.27

Notes

1. The operations of the Group relate to two segments viz.; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Nine Months Ended		Year Ended
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	2.92	4.10	30.02	52.02	30.02	68.82
b) Consultancy Services	1,102.67	1,208.15	1,341.22	3,527.74	2,833.84	6,463.42
Total Sales	1,105.59	1,212.25	1,371.24	3,579.76	2,863.86	6,532.24
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	1,105.59	1,212.25	1,371.24	3,579.76	2,863.86	6,532.24
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(15.17)	(6.18)	6.65	0.13	6.65	2.72
b) Consultancy Services	(746.82)	174.97	760.05	9.02	925.78	255.66
Total	(761.98)	168.79	766.70	9.16	1,024.22	258.38
Less: Interest	12.76	11.58	13.59	35.70	33.76	47.66
Total Profit before tax	(774.75)	157.21	753.11	(26.55)	990.47	210.72
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	78.84	306.53	279.54	78.84	279.54	261.13
b) Consultancy Services	3,023.67	3,870.71	4,003.62	3,023.67	4,003.62	3,933.17
Total Assets	3,102.51	4,177.24	4,283.16	3,102.51	4,283.16	4,194.30
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	8.97	12.24	17.20	8.97	17.20	8.17
b) Consultancy Services	554.02	879.11	1,933.37	554.02	1,933.37	1,770.21
Total Liabilities	562.99	891.35	1,950.57	562.99	1,950.57	1,778.38

2. The Exceptional items represents security deposits written off which are not recoverable.

3. The above results for the Quarter ended 31 December 2022 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.02.2023.

4. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

5. The above results as of 31.12.2022 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

6. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

7. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 14.02.2023



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 31st December, 2022 and year to date results for the period 1st April, 2022 to 31st December, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)

K.Sreenivasan
Partner
Membership No.206421

UDIN: 23206421BGTHNE5745

Place : Secunderabad
Date : 14.02.2023





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015

Review Report to The Board of Directors

Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 31st December, 2022 and year to date results for the period 1st April, 2022 to 31st December, 2022 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable
4. The Statement includes the results of the subsidiaries Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain.




Ramanatham & Rao

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total assets of of Rs. 3010.74 Lakhs as at 31st December, 2022, total revenues of Rs. 1102.67 lakhs and Rs. 3511.70 lakhs, total net profit (Loss) after tax of Rs (539.91) lakhs and Rs. 165.26 lakhs, total comprehensive Income of Rs. 29.39 lakhs and Rs. 188.59 lakhs for the quarter ended 31st December, 2022 and for the period from 1st April, 2022 to 31st December, 2022 respectively as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan
Partner
Membership No.206421

UDIN: 23206421BGTHNF1170

Place : Secunderabad
Date : 14.02.2023

